Morita Masashi, Matsumoto Shun, Sato Airi, Inoue Kengo, Kostsin Dzmitry G, Yamazaki Kozue, Kawaguchi Kosuke, Shimozawa Nobuyuki, Kemp Stephan, Wanders Ronald J, Kojima Hirotatsu, Okabe Takayoshi, Imanaka Tsuneo
Department of Biological Chemistry, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Institute of Biophysics and Cell Engineering, National Academy of Sciences of Belarus, Minsk, Belarus.
JIMD Rep. 2019;44:23-31. doi: 10.1007/8904_2018_118. Epub 2018 Jun 21.
Mutations in the ABCD1 gene that encodes peroxisomal ABCD1 protein cause X-linked adrenoleukodystrophy (X-ALD), a rare neurodegenerative disorder. More than 70% of the patient fibroblasts with this missense mutation display either a lack or reduction of the ABCD1 protein because of posttranslational degradation. In this study, we analyzed the stability of the missense mutant ABCD1 proteins (p.A616T, p.R617H, and p.R660W) in X-ALD fibroblasts and found that the mutant ABCD1 protein p.A616T has the capacity to recover its function by incubating at low temperature. In the case of such a mutation, chemical compounds that stabilize mutant ABCD1 proteins could be therapeutic candidates. Here, we prepared CHO cell lines stably expressing ABCD1 proteins with a missense mutation in fusion with green fluorescent protein (GFP) at the C-terminal. The stability of each mutant ABCD1-GFP in CHO cells was similar to the corresponding mutant ABCD1 protein in X-ALD fibroblasts. Furthermore, it is of interest that the GFP at the C-terminal was degraded together with the mutant ABCD1 protein. These findings prompted us to use CHO cells expressing mutant ABCD1-GFP for a screening of chemical compounds that can stabilize the mutant ABCD1 protein. We established a fluorescence-based assay method for the screening of chemical libraries in an effort to find compounds that stabilize mutant ABCD1 proteins. The work presented here provides a novel approach to finding therapeutic compounds for X-ALD patients with missense mutations.
编码过氧化物酶体ABCD1蛋白的ABCD1基因突变会导致X连锁肾上腺脑白质营养不良(X-ALD),这是一种罕见的神经退行性疾病。超过70%携带这种错义突变的患者成纤维细胞由于翻译后降解而表现出ABCD1蛋白缺失或减少。在本研究中,我们分析了X-ALD成纤维细胞中错义突变的ABCD1蛋白(p.A616T、p.R617H和p.R660W)的稳定性,发现突变的ABCD1蛋白p.A616T具有通过低温孵育恢复其功能的能力。对于这种突变情况,稳定突变ABCD1蛋白的化合物可能是治疗候选物。在此,我们制备了稳定表达与绿色荧光蛋白(GFP)在C端融合的具有错义突变的ABCD1蛋白的CHO细胞系。每个突变的ABCD1-GFP在CHO细胞中的稳定性与X-ALD成纤维细胞中相应的突变ABCD1蛋白相似。此外,有趣的是,C端的GFP与突变的ABCD1蛋白一起被降解。这些发现促使我们使用表达突变ABCD1-GFP的CHO细胞来筛选能够稳定突变ABCD1蛋白的化合物。我们建立了一种基于荧光的检测方法来筛选化学文库,以寻找稳定突变ABCD1蛋白的化合物。本文介绍的工作为寻找患有错义突变的X-ALD患者的治疗化合物提供了一种新方法。